DelveInsight’s “Ductal Carcinoma in Situ Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Ductal Carcinoma in Situ, historical and forecasted epidemiology as well as the Ductal Carcinoma in Situ market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Ductal Carcinoma in Situ market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Ductal Carcinoma in Situ market outlook, drug uptake, treatment scenario and epidemiology trends @ https://www.delveinsight.com/sample-request/ductal-carcinoma-in-situ-market
Key Takeaways from Ductal Carcinoma in Situ Market Report
- In May 2026- Integro Theranostics conducted a Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.
- In April 2026- Julie Nangia initiated a study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
- In April 2026- City of Hope Medical Center announced a phase II trial tests the effectiveness of cannabidiol (CBD) plant extract (BRC-001) in improving joint stiffness and pain (arthralgia) in women with breast cancer taking aromatase inhibitors (AIs). AIs lower blood levels of estrogen in postmenopausal women to reduce breast cancer recurrence. Women on AI therapy may experience joint stiffness, pain and arthritis symptoms as a side effect of the medication. Some women stop AI therapy due to these side effects and do not receive the maximum benefit from the medication.
- Ductal Carcinoma in Situ clinical trials are advancing innovative therapies aimed at improving early breast cancer management, enhancing patient outcomes, and exploring novel treatment strategies for this non-invasive cancer stage.
- The leading Ductal Carcinoma in Situ Companies such as Atossa Therapeutics, Inc. , F. Hoffmann-La Roche , ImmunoRestoration Inc, SELLAS Life Sciences Group, Inc. , University of Pittsburgh , Marker Therapeutics, Inc. , and others.
- Promising Ductal Carcinoma in Situ Therapies such as Ruxolitinib, Afimoxifene, LS301-IT 0.025 mg/kg, letrozole, tamoxifen citrate, Anastrozole, AVB-620, BRC-001 and others.
Get a Free sample for the Ductal Carcinoma in Situ Market Report @ Ductal Carcinoma in Situ Treatment Market
Ductal Carcinoma in Situ Overview
Ductal Carcinoma in Situ (DCIS) is a non-invasive form of breast cancer where abnormal cells are found in the lining of breast ducts but have not spread beyond the duct wall into surrounding breast tissue. It is considered the earliest form of breast cancer and is often detected through routine mammography screening. While DCIS is non-invasive, if left untreated, it may progress to invasive breast cancer in some cases, making appropriate management crucial for patient outcomes.
Ductal Carcinoma in Situ Epidemiology
- Total Prevalent Cases of Ductal Carcinoma in Situ
- Diagnosed Prevalent Cases of Ductal Carcinoma in Situ
- Age-specific Cases of Ductal Carcinoma in Situ
- Gender-specific Cases of Ductal Carcinoma in Situ
- Stage-specific Cases of Ductal Carcinoma in Situ
- Country-wise Breakdown of Ductal Carcinoma in Situ
Download the report to understand which factors are driving Ductal Carcinoma in Situ epidemiology trends @ Ductal Carcinoma in Situ Prevalence
Ductal Carcinoma in Situ Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ductal Carcinoma in Situ market or expected to get launched during the study period. The analysis covers Ductal Carcinoma in Situ market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Ductal Carcinoma in Situ Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Ductal Carcinoma in Situ Therapies and Companies
Atossa Therapeutics Inc., F. Hoffmann-La Roche Ltd, ImmunoRestoration Inc., SELLAS Life Sciences Group Inc, University of Pittsburgh, Marker Therapeutics Inc., and others.
To know more about Ductal Carcinoma in Situ treatment, visit @ Ductal Carcinoma in Situ Medications
Ductal Carcinoma in Situ Market Drivers
- Rising awareness of early-stage breast cancer and the importance of screening programs
- Advancements in precision diagnostics and molecular testing, including breakthrough devices like DCISionRT®
- Increasing healthcare expenditure and improved access to oncology care globally
- Growing patient population due to enhanced detection through routine mammography screening
- Development of novel targeted therapies focused on personalized treatment approaches
- Better understanding of disease pathogenesis contributing to innovative therapeutic development
- Expansion of treatment options beyond traditional surgical and radiation approaches
- Increasing focus on improving quality of life and reducing overtreatment in early-stage disease
Ductal Carcinoma in Situ Market Barriers
- Challenges in differentiating patients who need aggressive treatment from those who can be managed conservatively
- Concerns about overtreatment and unnecessary interventions for low-risk DCIS cases
- High cost of advanced diagnostic tests and limited reimbursement in certain regions
- Stringent regulatory requirements and lengthy approval timelines for novel therapies
- Limited long-term efficacy data for emerging targeted treatments
- Variability in treatment guidelines across different geographic regions
- Patient anxiety and decision-making challenges regarding treatment options
- Lack of standardized risk stratification tools in clinical practice
Explore More Information of the Ductal Carcinoma in Situ Therapeutics Market Report @ Ductal Carcinoma in Situ Market Access and Reimbursement
Scope of the Ductal Carcinoma in Situ Market Report
- Coverage: 7MM
- Study Period: 2020-2034
- Forecast Period: 2024-2034
- Ductal Carcinoma in Situ Companies: Atossa Therapeutics, Inc. , F. Hoffmann-La Roche , ImmunoRestoration Inc, SELLAS Life Sciences Group, Inc. , University of Pittsburgh , Marker Therapeutics, Inc. , and others.
- Ductal Carcinoma in Situ Therapies: Multiple emerging therapies in Phase II and Phase III development stages
- Ductal Carcinoma in Situ Therapeutic Assessment: Current marketed and emerging therapies
- Ductal Carcinoma in Situ Market Dynamics: Market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Ductal Carcinoma in Situ Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
Table of Contents
- Key Insights
- Executive Summary of Ductal Carcinoma in Situ
- Competitive Intelligence Analysis for Ductal Carcinoma in Situ
- Ductal Carcinoma in Situ: Market Overview at a Glance
- Ductal Carcinoma in Situ: Disease Background and Overview
- Ductal Carcinoma in Situ Patient Journey
- Ductal Carcinoma in Situ Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Ductal Carcinoma in Situ Unmet Needs
- Key Endpoints of Ductal Carcinoma in Situ Treatment
- Ductal Carcinoma in Situ Marketed Products
- Ductal Carcinoma in Situ Emerging Therapies
- Ductal Carcinoma in Situ: Seven Major Market Analysis
- Attribute Analysis
- 7MM: Ductal Carcinoma in Situ Market Outlook
- Access and Reimbursement Overview of Ductal Carcinoma in Situ
- KOL Views
- Ductal Carcinoma in Situ Market Drivers
- Ductal Carcinoma in Situ Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
